Divis Laboratories has announced impressive Q4 financial results. Revenue increased by 12.20% to ₹2,585.00 crore, EBITDA rose by 21.20% to ₹886.00 crore, and net profit climbed by 23.00% to ₹662.00 crore compared to the previous year. The EBITDA margin improved to 34.27% from 31.74%. Quarter-on-quarter growth was also notable, with revenue up 7.66%, EBITDA up 7.39%, and net profit up 12.39% compared to Q3.
02May 25
Divi's Laboratories Sees Significant Block Trade on NSE
A significant block trade of approximately 100,045 shares of Divi's Laboratories Ltd. occurred on the National Stock Exchange (NSE), valued at Rs. 60.77 crores. The trade was executed at Rs. 6,074.50 per share, reflecting current market valuations for the pharmaceutical company. This large transaction is likely to impact the day's trading volume and may attract attention from market participants.
02May 25
Divi's Laboratories Sees Significant Block Trade on NSE
A significant block trade of 144,937 shares of Divi's Laboratories Ltd. occurred on the National Stock Exchange (NSE) at Rs. 6,114.00 per share, totaling Rs. 88.61 crores. This large transaction could potentially indicate a shift in institutional holdings or a strategic move by a major investor. Divi's Laboratories, known for manufacturing active pharmaceutical ingredients and intermediates, is a key player in the Indian pharmaceutical sector.
21Apr 25
Divi's Laboratories Inks Long-term Manufacturing Deal and Unveils Expansion Plans
Divi's Laboratories has entered a long-term manufacturing agreement with a global pharmaceutical company for advanced intermediates. Additionally, the company plans to invest Rs 650-700 crore in a capacity expansion project, funded entirely through internal resources. These moves aim to strengthen Divi's market position and manufacturing capabilities in the pharmaceutical industry.
19Apr 25
Divi's Laboratories Secures Long-Term Manufacturing Deal and Announces Expansion Plans
Divi's Laboratories has entered into a long-term manufacturing agreement with a global pharmaceutical company for advanced intermediates. Additionally, the company plans to invest Rs 650-700 crore in a capacity expansion project, to be funded internally. These moves aim to strengthen Divi's market position and manufacturing capabilities in the pharmaceutical sector.
Divi's Laboratories has secured a long-term supply agreement with a global pharmaceutical company for advanced intermediates. The company expects significant revenue contributions from this deal in the coming years. To support this and future growth, Divi's plans to invest Rs 650-700 crore in capacity expansion, funded entirely through internal accruals.
11Apr 25
Divis Laboratories Reports 22% Growth in Exports, Reaching $85 Million
Divis Laboratories, a leading Indian CDMO, has reported significant export growth. Annual exports reached $85.00 million, a 22% year-over-year increase. The fourth quarter saw a 23% surge compared to the previous year. This growth underscores Divis' expanding role in the global pharmaceutical supply chain and suggests increasing demand for its services internationally.
21Feb 25
Divi's Laboratories Sees Significant Block Trade on NSE
A significant block trade of 203,922 shares of Divi's Laboratories Ltd. occurred on the National Stock Exchange at Rs. 5,790.00 per share, totaling Rs. 118.07 crores. The transaction, likely involving institutional investors, has drawn market attention due to its scale. While the parties involved remain undisclosed, such trades can potentially influence stock prices and indicate shifts in institutional holdings.